Intra-cellular therapies announces executive appointments and leadership changes

New york, march 19, 2024 (globe newswire) -- intra-cellular therapies, inc. (nasdaq: itci), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, today announced the promotion of michael halstead, j.d. to the position of president. mr. halstead is currently serving as executive vice president and general counsel. in this newly created leadership role, mr. halstead will oversee several functions within the company including legal, human resources, manufacturing & supply chain, quality, compliance, information technology, and external innovation. he will continue to report to dr. sharon mates, chairman and chief executive officer.
ITCI Ratings Summary
ITCI Quant Ranking